Group Leader at UK DRI at UCL, Prof Sarah Tabrizi, has been awarded two separate honours for her contribution to Huntington’s disease research. Last month, Prof Tabrizi picked up the Yahr award at the World Congress of Neurology in Dubai, before collecting the Alexander Morison medal from the Royal College of Physicians of Edinburgh (RCPE) on Tuesday (5 Nov).
Recognition of Sarah’s work follows positive results from a Phase 1/2a trial, led by herself and sponsored by Ionis Pharmaceutical, indicating that the first drug targeting the cause of the disease was safe, well-tolerated and successfully lowered the level of harmful huntingtin protein in the nervous system. With no current disease-modifying therapeutics for the condition, the development of the antisense oligonucleotide (ASO) treatment is a breakthrough not only for Huntington’s disease, but for the prospect of gene targeting therapies in the future. Listen to a recent BBC interview with Sarah here.
On the two awards, Prof Sarah Tabrizi said:
“I am deeply honoured to receive these awards for my work in Huntington's disease. They are recognition of the tireless efforts of the people affected and their families, and of the colleagues I continue to work with, to find effective therapies for this devastating disease. I'm so very grateful for their support.”